$ARMP News

Why Is Armata Pharma Stock Gaining Monday?

Armata Pharma Promotes David House To CFO

Armata Announces Significant Clinical, Regulatory, Manufacturing And Operational Progress Supporting Advancement Of AP-SA02 Toward Planned Phase 3 Superiority Study For Adjunct Treatment Of Complicated Bacteremia

Armata Pharmaceuticals: Promising Phage Platform, But Phase 3 Is Everything

Armata Pharma Receives Agreement From FDA On Agreed Initial Pediatric Study Plan

Armata Pharma Receives Additional $2.5M Of Non-Dilutive DoD Funding Via Medical Technology Enterprise Consortium, Managed By Naval Medical Research Command

Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update

Armata Pharmaceuticals Q1 EPS $(3.16) Misses $(0.38) Estimate, Sales $789.000K Up From $491.000K YoY

Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02

Armata Pharmaceuticals Granted FDA's Fast Track Designation For AP-SA02 To Treat Bacterial Infections

Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"

Armata Pharmaceutics Announces Publication Of Paper In 'Communications Biology,' A Peer-Reviewed Journal From Nature Portfolio

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results

Armata Pharmaceuticals Q4 EPS $(3.43) Misses $(0.28) Estimate, Sales $1.085M Beat $750.000K Estimate

Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update

Armata Pharmaceuticals To Delay Announcement Of Q4, FY25 Financial Results; Provides Corporate Update

Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags

H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod

Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02

HC Wainwright & Co. Maintains Buy on Armata Pharmaceuticals, Raises Price Target to $15